The Urgent Need of Reliable and Approved Vaccination for COVID-19 Novel Corona Virus in Current Pandemic

The Urgent Need of Reliable and Approved Vaccination for COVID-19 Novel Corona Virus in Current Pandemic.


Introduction
More than 90 vaccines [1] are being developed against SARS-CoV-2 by research teams in companies and universities across the world. Researchers are trialing different technologies some of which haven't been used in a licensed vaccine before. At least six groups have already begun injecting formulations into volunteers in safety trials others have started testing in animals. Nature's graphical guide explains each vaccine design. All vaccines aim to expose the body to an antigen that won't cause disease but will provoke an immune response that can block or kill the virus if a person becomes infected. There are at least eight types being tried against the coronavirus, and they rely [1] [2] plans to initiate human testing in 2020.
Sharing knowledge with [3,4] parallel COVID-19 vaccine efforts worldwide is crucial. WHO is in the process of creating a forum for everyone who is developing COVID-19 vaccines to come together and present their plans and initial findings? It is essential that we all measure immunological responses to the various vaccines in the same way to ensure comparability and generalizability of our collective findings. Work is continuing at a very fast pace and I am in no doubt that we will see an unprecedented spirit of collaboration and cooperation convened by WHO as we move towards a shared [4] global goal of COVID-19 prevention through vaccination ( Figure   1). The G7 committed to [5] supporting the launch of joint research projects for COVID-19 treatments and vaccines.12 High-level dialogue is needed on ways to ensure complementarity of efforts and global access to COVID-19 vaccines. Investments should proceed in tandem to build national systems for delivery of potential vaccines for example using domestic financing and external financing from   One of the crucial mistakes [6] made at the time by French authorities was to refuse to communicate early on the measures taken to ensure the safety of the vaccine for fear that the mere evocation of risk might provoke irrational reactions. This approach let critics set the agenda on this issue condemning public authorities to a defensive position. Public authorities are setting up fast-track approval processes for a putative [6][7][8][9][10] vaccine against SARS-CoV-2.9 It is crucial to communicate early and transparently on these processes to avoid vaccines becoming part of political debates. As the world is witnessing the [11]    To address this global crisis [12] up-to-date information on viral genomics and transcriptomics is crucial for understanding the origins and global dispersion of the virus providing insights into viral pathogenicity transmission and epidemiology and enabling strategies for therapeutic interventions drug discovery and vaccine development. Therefore, this review provides a comprehensive overview of COVID-19 epidemiology genomic etiology findings from recent transcriptomic map analysis viral-human protein interactions molecular diagnostics and the current status of vaccine and novel therapeutic intervention development. Moreover, we provide an extensive list of resources that will help the scientific community access numerous types of databases related to SARS-CoV-2 OMICs and [12] approaches to therapeutics related to COVID-19 treatment.

Methods
The Methodology used in this Article is Critical Literature review where Author has presented the Table 1

Results
Author of this article have presented the results by using diagrams from SPSS19 software. After studying and carefully critically reviewing the 21 Articles and other sources and randomly selecting 15 Articles for Urgent Need of reliable and approved Vaccination for COVID-19. First part of the result in Table 1 and  Predicting the next source of the [7] pandemic can be very challenging. As vaccination is the best way to prevent an infectious disease the development of an effective vaccine against SARS-CoV-2 can not only reduce the morbidity and mortality associated with it but can also lessen the economic impact. As the traditional method of vaccine development takes many years for a vaccine to be available to the society the vaccine development for SARS-CoV-2 should be speeded up using a pandemic approach with fast-track approvals from the regulatory authorities. Various challenges associated with developing a vaccine during the pandemic such as technological hurdles clinical development pathways regulatory issues, and support from global [7] funding agencies are expressed here (Figure 8). Significant progress [16] has been made in the The outbreak has led to [17] [19,20] vaccine candidates that could follow stood at 52.
In the midst of a pandemic it is [21] reasonable to require certain qualities in candidate vaccines as described above and to